



Docket No. 08-1238

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zhang et al.

Serial No. : 09/603,338

Art Unit: 1614

Filed : June 26, 2000

Examiner: R. Raseur

For : NOVEL INDOLE PEPTIDOMETICS AS THROMBIN RECEPTOR
ANTAGONISTS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Assistant Commissioner For Patents, Washington, D.C. 20231 on

November 5, 2001
(Date of Deposit)

Hal B. Woodrow
(Name of applicant, assignee, or Registered Representative)

Hal Bunt Woodrow
(Signature)

November 5, 2001
(Date of Signature)

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this
information may not be prior art, and/or to prove that this

RECEIVED
1614
DEC 12 2001
TECH CENTER
12/28/01
#5

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: Nitrogenous heterocyclic derivatives having an $\alpha_v\beta_3$ integrin inhibitory activity, and being useful for inhibiting neovascularization and preventing post-PTCA restenosis, or salts thereof, and a medicinal composition containing the same.

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.


☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1238/HBW. This form is submitted in triplicate.

Respectfully submitted,

Hal B. Woodrow
Hal B. Woodrow
Reg. No. 32,501
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
DATED: November 5, 2001



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number	09/603,338
Filing Date	June 26, 2000
First Named Inventor	Zhang et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1238

[illegible]

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	92/14750 ✓	A1	Coughlin et al.	Sept. 3, 1992	All	
		CA	2,011,222 ✓	A1	Bru-Magniez et al.	March 1990	All	
		EP	0 385 850 ✓	A2	Bru-Magniez et al.	Sept. 1990	All	
		WO	93/18026 ✓	A1	Forbes et al.	Sept. 16, 1993	All	
		WO	99/00357 ✓	A1	Salituro et al.	Jan. 7, 1999	All	
		WO	99/33798 ✓	A1	Akamatsu et al.	July 8, 1999		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECOVER